Suven Pharma Q3 Results: Net profit surges 78% to Rs 83 crore, revenue up 40%

PE firm Advent backed Suven Pharma net profit rose 78% year-on-year (YoY) to Rs 83.3 crore in Q3FY25 compared to Rs 46.8 crore in the corresponding period of the previous year.

Revenue grew 40% YoY to Rs 307.2 crore in Q3FY25 driven by doubling of CDMO business driven by R&D and business development efforts.

Gross margins for the quarter stood at 71.5% and adjusted EBITDA margins stood at 38.7%.

The Hyderabad-based company said it is seeing strong demand across stages on the back of secular macro tailwinds.
It said two molecules added this quarter in which one molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.

It also said a previously highlighted positive readout on Phase III molecule has now met the primary endpoint for a second indication and onboarded a new strategic customer – one of the top five global pharma leaders for early-to-mid-phase projects.

“We continue to make business development efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision,’ said Vivek Sharma, executive chairman.”Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth,” Sharma added.

READ SOURCE